These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 9591522

  • 21. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group.
    Lancet; ; 365(9463):947-54. PubMed ID: 15766996
    [Abstract] [Full Text] [Related]

  • 22. Highlights of the North American and European experiences.
    Goetz CG.
    Neurology; 1998 May; 50(5 Suppl 5):S15-6. PubMed ID: 9591517
    [Abstract] [Full Text] [Related]

  • 23. The effect of tolcapone on the pharmacokinetics of benserazide.
    Jorga KM, Larsen JP, Beiske A, Schleimer M, Fotteler B, Schmitt M, Moe B.
    Eur J Neurol; 1999 Mar; 6(2):211-9. PubMed ID: 10053234
    [Abstract] [Full Text] [Related]

  • 24. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH, Spieker S, Clarke CE.
    Cochrane Database Syst Rev; 2004 Oct 18; 2004(4):CD004554. PubMed ID: 15495119
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators.
    Lancet Neurol; 2016 Feb 18; 15(2):154-165. PubMed ID: 26725544
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ, Rocha JF, Falcão A, Santos A, Pinto R, Nunes T, Soares-da-Silva P.
    Eur J Neurol; 2015 May 18; 22(5):815-25, e56. PubMed ID: 25649051
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ, Sagar H, UK-Irish Entacapone Study Group.
    J Neurol Neurosurg Psychiatry; 2003 Aug 18; 74(8):1071-9. PubMed ID: 12876237
    [Abstract] [Full Text] [Related]

  • 33. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM, Rinne UK.
    J Neurol; 1998 Nov 18; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE, Jorga K, Crevoisier C, Hovens SE, van Giersbergen PL.
    Eur Neurol; 1999 Nov 18; 41(4):206-11. PubMed ID: 10343151
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.